Drug Profile
Research programme: cancer and fibrosis therapeutics - iOnctura
Alternative Names: Anti-CD73 Ab - CRT/iOnctura/Merck; Anti-CXCL12 Ab - CRT/iOnctura/Merck; Anti-lag Ab - CRT/iOnctura/MerckLatest Information Update: 28 Jan 2024
Price :
$50
*
At a glance
- Originator Cancer Research Technology; Merck KGaA
- Developer Cancer Research Technology; iOnctura; Merck KGaA
- Class Antibodies; Antifibrotics; Antineoplastics; Small molecules
- Mechanism of Action CD223 antigen inhibitors; Chemokine CXCL12 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours